EXOS 25 - Pharmacom Labs

Exemestane, marketed as Aromasin, is a potent steroidal aromatase inhibitor developed by Pharmacia & Upjohn and approved by the FDA in 1999. It effectively reduces estrogen levels by inhibiting the enzyme responsible for estrogen synthesis, making it valuable in breast cancer treatment. Bodybuilders use it off-label to combat estrogenic side effects from steroid use, such as gynecomastia and water retention. Exemestane lowers serum estrogen levels by approximately 85%, helping athletes maintain a leaner, more defined physique during cycles .

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about EXOS 25 by Pharmacom Labs, consult with your doctor or healthcare professional.